Detalhe da pesquisa
1.
Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human.
Nucleic Acids Res
; 39(18): 7946-60, 2011 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-21729870
2.
BET Inhibition Enhances TNF-Mediated Antitumor Immunity.
Cancer Immunol Res
; 10(1): 87-107, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34782346
3.
A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis.
AAPS J
; 24(1): 7, 2021 12 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34862519
4.
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid.
Pharmaceutics
; 13(12)2021 Dec 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34959386
5.
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Front Oncol
; 11: 650149, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33614518
6.
Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.
Elife
; 102021 08 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34378534
7.
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Front Oncol
; 10: 575737, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-33330050
8.
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Sci Transl Med
; 11(496)2019 06 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31189721
9.
Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells.
Oncol Rep
; 18(2): 497-501, 2007 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-17611676
10.
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Cancer Cell
; 31(3): 396-410, 2017 03 13.
Artigo
Inglês
| MEDLINE | ID: mdl-28262554
11.
Induction of PPARbeta and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARbeta.
FEBS J
; 273(1): 170-9, 2006 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-16367757
12.
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
J Immunother
; 39(7): 279-89, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27404941
13.
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
Clin Cancer Res
; 22(17): 4417-27, 2016 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27117182
14.
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Clin Cancer Res
; 22(13): 3286-97, 2016 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26861458
15.
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Mol Cancer Ther
; 12(10): 2031-42, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23873847
16.
miR-155 inhibition sensitizes CD4+ Th cells for TREG mediated suppression.
PLoS One
; 4(9): e7158, 2009 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-19777054